GSK plc (GSK.L) Tuesday said it has agreed to acquire Aiolos Bio, Inc., a clinical-stage biopharmaceutical company developing treatments for certain respiratory and inflammatory conditions.
The deal includes $1 billion upfront payment and up to $400 million in milestone payments.
The acquisition adds Aiolos' AIO-001, a long-acting anti-thymic stromal lymphopoietin (TSLP) monoclonal antibody, to GSK's respiratory pipeline. AIO-001 is ready to enter Phase 2 study for the treatment of adults with asthma.
AIO-001 was exclusively licensed to Aiolos outside of Greater China by Jiangsu Hengrui Pharmaceuticals Co., Ltd.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.